Zenas BioPharma, Inc. (ZBIO)
29.53
+1.27
(+4.49%)
USD |
NASDAQ |
Nov 09, 14:42
Zenas BioPharma Gross Profit Margin (Quarterly) : 99.96% for Sept. 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 99.96% |
| June 30, 2026 | 99.60% |
| March 31, 2026 | |
| December 31, 2025 | |
| September 30, 2025 | |
| June 30, 2025 | |
| March 31, 2025 | 99.77% |
| Date | Value |
|---|---|
| December 31, 2024 | 99.34% |
| September 30, 2024 | |
| June 30, 2024 | |
| March 31, 2024 | |
| December 31, 2023 | |
| September 30, 2023 | 99.95% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 89.75% |
| Alnylam Pharmaceuticals, Inc. | 75.19% |
| Anika Therapeutics, Inc. | 61.57% |
| Savara, Inc. | -- |
| Vericel Corp. | 73.34% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -219.6% |
| Return on Assets | -95.72% |
| Return on Invested Capital | -110.3% |
| Profit Margin (Quarterly) | -1.09K% |
| Operating Margin (Quarterly) | -759.1% |
| Return on Net Operating Assets | -35.13K% |